Thomas Hagedorn - Electromed Independent Director

<div class='circular--portrait' style='background:#689CFD;color: #ffffff;font-size:4em;padding-top: 25px;;'>EL</div>
ELMD -- USA Stock  

Fiscal Quarter End: 30th of June 2020  

  Director
Mr. Thomas M. Hagedorn is Independent Director of Electromed Inc. He has also served for approximately fifteen years as president of entities in a of real estate and mortgage companies headquartered in Northern Virginia namely Premium Financial Services Premium Realty Ltd. and Premium Title Services a mortgage company real estate brokerage company and title insurance company respectively. As president of these entities Mr. Hagedorn manages all aspects of the companies activities including managing between one to five employees in each company maintaining records and funds with respect to escrow accounts of clients and coordinating responses in connection with regulatory audits of the escrow accounts managed by each company. Mr. Hagedorn has also been a founding investor for various startup ventures including Hansen Engine Corporationrationration as well as several energy companies where new technology is a principal factor. Mr. Hagedorn is a former member of the Minnesota State Legislature and the U.S. Congress representing southern Minnesota.
Age: 67  Director Since 1997      
952 758 9299  http://www.smartvest.com

Electromed Management Efficiency

Electromed has return on total asset (ROA) of 0.0716 % which means that it generated profit of $0.0716 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of 0.0696 % meaning that it created $0.0696 on every $100 dollars invested by stockholders. Electromed management efficiency ratios could be used to measure of how well the company is managing its routine affairs as well as how well it utilizes its assets and manages liabilities. As of June 5, 2020, Return on Average Assets is expected to decline to 0.0007. In addition to that, Return on Average Equity is expected to decline to 0.0007Electromed Asset Turnover is expected to slightly increase based on the last few years of reporting. The last year's Asset Turnover was at 1.29. Electromed Liabilities Non Current is expected to significantly decrease based on the last few years of reporting. The last year's Liabilities Non Current was at 13,263.3
The company currently holds 122.57 K in liabilities with Debt to Equity (D/E) ratio of 0.4 which is about average as compared to similar companies. Electromed has Current Ratio of 8.6 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Showing few of many executives

DIRECTOR Since

Argil WheelockEDAP TMS SA
2009
Lisa GershEstablishment Labs Holdings
2019
Dimitrios AngelisDigirad
2015
Sean CloskeyESCALON MEDICAL CORP
2013
Michael CunnionDigirad
2014
Todd TruskESCALON MEDICAL CORP
2015
David JacoviniESCALON MEDICAL CORP
2018
John DogumESCALON MEDICAL CORP
2018
Barbara McNeilEdwards Lifesciences Corporatio
2006
Lisa ColleranEstablishment Labs Holdings
2015
Erin EnrightDynatronics
2018
Fred ChoateESCALON MEDICAL CORP
2005
Martha MarshEdwards Lifesciences Corporatio
2020
Scott KlostermanDynatronics
2016
Mitchell QuainDigirad
2019
Aaron MendelsohnSecond Sight Medical
N/A
Pierre BeyssonEDAP TMS SA
2002
John CardisEdwards Lifesciences Corporatio
2004
Charles GillmanDigirad
2012
David HoltzDynatronics
2015
Robrecht MichielsEDAP TMS SA
2009

Company Summary

Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation therapy in pulmonary care for patients of all ages in the United States and internationally. The company was founded in 1992 and is headquartered in New Prague, Minnesota. Electromed operates under Medical Devices classification in USA and is traded on BATS Exchange. It employs 119 people.Electromed (ELMD) is traded on BATS Exchange in USA. It is located in 500 Sixth Avenue NW and employs 119 people. Electromed is listed under Medical Equipment category by Fama And French industry classification.

Electromed Leadership Team

Kathleen Skarvan, CEO and President and Director
George Winn, Vice Chairman of the Board
Thomas Hagedorn, Independent Director
Stephen Craney, Independent Chairman of the Board
Stan Erickson, Independent Director
William Eckles, Independent Director
Jeremy Brock, CFO
Lee Jones, Director

Stock Performance Indicators

Did you try this?

Run CEO Directory Now

   

CEO Directory

Screen CEOs from public companies around the world
All  Next Launch Module

Electromed Pair Correlation

Equities Pair Trading Analysis

Correlation analysis and pair trading evaluation for Electromed and Edwards Lifesciences. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Continue to Investing Opportunities. Please also try Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page